Coastline Trust Co purchased a new position in AstraZeneca plc (NYSE:AZN) in the first quarter, HoldingsChannel.com reports. The fund purchased 5,075 shares of the company’s stock, valued at approximately $205,000.
A number of other large investors have also recently bought and sold shares of AZN. Bank of New York Mellon Corp grew its stake in AstraZeneca by 5.9% in the third quarter. Bank of New York Mellon Corp now owns 188,336 shares of the company’s stock worth $7,452,000 after purchasing an additional 10,560 shares in the last quarter. Credit Suisse AG boosted its stake in AstraZeneca by 73.9% in the third quarter. Credit Suisse AG now owns 18,873 shares of the company’s stock valued at $746,000 after acquiring an additional 8,023 shares during the period. Jane Street Group LLC boosted its stake in AstraZeneca by 278.6% in the third quarter. Jane Street Group LLC now owns 16,490 shares of the company’s stock valued at $653,000 after acquiring an additional 12,135 shares during the period. Mackenzie Financial Corp boosted its stake in AstraZeneca by 8.2% in the third quarter. Mackenzie Financial Corp now owns 29,680 shares of the company’s stock valued at $1,174,000 after acquiring an additional 2,247 shares during the period. Finally, Neuberger Berman Group LLC boosted its stake in AstraZeneca by 174.2% in the third quarter. Neuberger Berman Group LLC now owns 527,906 shares of the company’s stock valued at $20,890,000 after acquiring an additional 335,355 shares during the period. Institutional investors and hedge funds own 18.32% of the company’s stock.
Shares of NYSE:AZN opened at $37.99 on Monday. AstraZeneca plc has a 12 month low of $34.38 and a 12 month high of $43.29. The company has a market cap of $96.22 billion, a P/E ratio of 10.98, a PEG ratio of 1.16 and a beta of 0.51. The company has a current ratio of 0.96, a quick ratio of 0.78 and a debt-to-equity ratio of 1.24.
A number of equities research analysts have recently weighed in on AZN shares. Cowen raised AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $42.00 to $48.00 in a report on Monday, April 1st. ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, April 1st. UBS Group cut AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price target on the stock. in a report on Tuesday, April 2nd. Goldman Sachs Group reaffirmed a “sell” rating on shares of AstraZeneca in a report on Tuesday, February 26th. Finally, Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. AstraZeneca currently has an average rating of “Hold” and a consensus target price of $45.29.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: NASDAQ
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.